Rare deleterious mutations in Bruton’s tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight

被引:0
作者
Jaishree Meena
Yasha Hasija
机构
[1] Delhi Technological University,Department of Biotechnology
来源
Journal of Molecular Modeling | 2023年 / 29卷
关键词
Bruton’s tyrosine kinase; Ibrutinib; MD simulation; Molecular docking; Contact map analysis; Mutational analysis; Protein-ligand interaction;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 19 条
[1]  
Fania L(2021)Cutaneous squamous cell carcinoma: From pathophysiology to novel therapeutic approaches Biomedicines 9 1-33
[2]  
GeidelG HI(2022)Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma Npj Precision Oncology 6 1-8
[3]  
Kött J(2008)‘The tumor microenvironment and its role in promoting tumor growth Oncogene 27 5904-13
[4]  
Schneider SW(2004)‘A census of human cancer genes Nat Rev Cancer 4 177-219
[5]  
Pantel K(2015)‘Targets for ibrutinib beyond B cell malignancies Scand J Immunol 82 208-25
[6]  
Gebhardt C(2020)‘Inferring the molecular and phenotypic impact of amino acid variants with MutPred2 Nat Commun 11 1-413
[7]  
Whiteside TL(2017)‘Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling Mol Pharmacol 91 208-583
[8]  
Futreal PA(2015)‘GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers SoftwareX 1–2 19-9508
[9]  
Berglöf A(2017)‘CHARMM36m: An improved force field for folded and intrinsically disordered proteins Nat Methods 14 71-713
[10]  
Pejaver V(2016)CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field J Chem Theory Comput 12 405-406